Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening thrombotic microangiopathy, with an estimated incidence of 2–6 cases per million annually. It is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ ischemia. While neurological and hematological manifestations are well-documented, data on renal involvement remain limited. This study aims to evaluate kidney outcomes in patients with acquired TTP.
We conducted a retrospective study at our institution over an 8-year period (2017–2025), including adult patients (age >16 years) diagnosed with acquired TTP. Demographic and clinical data, renal involvement, therapeutic management, and mortality rates were analyzed using descriptive statistics.
Sixteen patients were diagnosed with acquired TTP, with a mean age of 42.3 years and a female-to-male ratio of 1:1. Emirati patients comprised 25% of the cohort. Comorbidities included hypertension (31.25%, n=5), obesity (BMI >30; 68.75%, n=11), chronic kidney disease (18.75%, n=3), and diabetes mellitus (25%, n=4). Diagnosis of acquired TTP was confirmed by the presence of microangiopathic hemolytic anemia (mean hemoglobin 79.3 g/L), thrombocytopenia (mean platelet count 16.3 × 10⁹/L), low ADAMTS13 activity with elevated inhibitors, and high PLASMIC scores. Renal involvement at presentation varied: normal renal function (n=5, 31.25%), AKI stage I (n=7, 43.75%), and AKI stage III requiring renal replacement therapy (n=3, 18.75%). Neurological manifestations ranged from confusion and seizures to acute ischemic strokes and subarachnoid hemorrhage. Critical care admission was required in 43.75% (n=7), with 37.5% (n=6) requiring intubation. Bacterial infections were documented in 43.75% (n=7). Coexisting conditions included hairy cell leukemia (n=1), IgA nephropathy with a left renal mass (n=1), and systemic lupus erythematosus (n=1). All patients received corticosteroids and therapeutic plasma exchange. Rituximab was administered in 87.5%, and caplacizumab in 50%. Most patients achieved normal renal function on follow-up; however, two patients (12.5%) progressed to end-stage renal disease due to delayed diagnosis prior to referral. The median hospital stay was 16 days, and the 90-day mortality rate was 12.5% (n=2).
Renal involvement in acquired TTP was heterogeneous: one-third had normal renal function, nearly half had AKI stage I, and a minority developed severe AKI requiring dialysis. Early diagnosis and prompt initiation of therapy including (plasma exchange, corticosteroids, rituximab, and caplacizumab ) were associated with favourable renal outcomes. Screening for underlying infections, autoimmune diseases, or malignancies is essential in the management of acquired TTP.
